Skip to main content

What the FDA labels say about taking them together

Arformoterol and umeclidinium/vilanterol

Umeclidinium/vilanterol's FDA label of June 2, 2023 names arformoterol in its warnings and precautions section; the arformoterol label PlainMeds reads does not name umeclidinium/vilanterol.

Check it at the source: the arformoterol FDA label on DailyMed (effective April 14, 2026, Sun Pharmaceutical Industries, Inc.); the umeclidinium/vilanterol FDA label on DailyMed (effective June 2, 2023, GlaxoSmithKline LLC).

What does the arformoterol label say about umeclidinium/vilanterol?

Arformoterol's label (effective April 14, 2026) does not name umeclidinium/vilanterol in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Arformoterol Tartrate), Sun Pharmaceutical Industries, Inc., effective April 14, 2026 (SPL set f1005878-0c48-4b9a-843e-b6cf6b8bb251), via openFDA; the full label on DailyMed

What does the umeclidinium/vilanterol label say about arformoterol?

Umeclidinium/vilanterol label, warnings and precautions

Patients using ANORO ELLIPTA should not use another therapy containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.

Source: FDA drug label (Anoro Ellipta), GlaxoSmithKline LLC, effective June 2, 2023 (SPL set 2dbd0671-c565-40c5-bf0f-e324db26799c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

15Arformoterol generic labelers
0Umeclidinium/vilanterol generic labelers
ArformoterolUmeclidinium/vilanterol
Labeled forCOPDCOPD
Boxed warningNoNo
Pharmacy cost (NADAC)$0.633 per mL 15 mcg/2 mL solution$4.95 per inhaler 62.5-25 mcg inhaler
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?